JOHNSON & JOHNSON
10-Q/A, 1996-08-09
PHARMACEUTICAL PREPARATIONS
Previous: JOHNSON & JOHNSON, 10-Q, 1996-08-09
Next: CITY NATIONAL CORP, 10-Q, 1996-08-09





             UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                       WASHINGTON, D.C.  20549

                AMENDMENT #1 EXHIBIT 27 BEING ADDED TO THE 10Q

                               FORM 10-Q

             X  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
                  OF THE SECURITIES EXCHANGE ACT OF 1934

               For the quarterly period ended June 30, 1996

                                    OR

               TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
                  OF THE SECURITIES EXCHANGE ACT OF 1934


      For the transition period from               to                

- -----------------------------------------------------------------

                       Commission file number 1-3215


                              JOHNSON & JOHNSON                     
          (Exact name of registrant as specified in its charter)


                NEW JERSEY                     22-1024240         
     (State or other jurisdiction of        (I.R.S. Employer
      incorporation or organization)         Identification No.)


                     New Brunswick, New Jersey  08933
       (Address of principal executive offices, including zip code)

                               908-524-0400 
            Registrant's telephone number, including area code 


     Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements
for the past 90 days.

                  Yes    X            No        

     Indicate the number of shares outstanding of each of the
issuer's classes of common stock, as of the latest practicable
date.

     On July 26, 1996, 1,332,644,572 shares of Common Stock, $1.00
par value, were outstanding.






<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-29-1996
<PERIOD-END>                               JUN-30-1996
<CASH>                                           1,860
<SECURITIES>                                        98
<RECEIVABLES>                                    3,652
<ALLOWANCES>                                       272
<INVENTORY>                                      2,506
<CURRENT-ASSETS>                                 9,244
<PP&E>                                           8,584
<DEPRECIATION>                                   3,335
<TOTAL-ASSETS>                                  19,305
<CURRENT-LIABILITIES>                            4,399
<BONDS>                                              0
<COMMON>                                         1,535
                                0
                                          0
<OTHER-SE>                                       8,705
<TOTAL-LIABILITY-AND-EQUITY>                    19,305
<SALES>                                         10,716
<TOTAL-REVENUES>                                     0
<CGS>                                            3,451
<TOTAL-COSTS>                                    3,451
<OTHER-EXPENSES>                                   876
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  65
<INCOME-PRETAX>                                  2,243
<INCOME-TAX>                                       662
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     1,581
<EPS-PRIMARY>                                     1.19
<EPS-DILUTED>                                     1.16
        

</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission